Dogs can have CBG (cannabigerol), and it appears to be one of the better-tolerated cannabinoids for animals based on the limited research available. CBG is a non-intoxicating compound found in hemp and cannabis plants, distinct from THC and CBD, and it has shown promising effects in animal studies without the neurotoxicity associated with some other cannabinoids. That said, veterinary research on CBG specifically in dogs is still thin, so what we know comes largely from studies in other animals and from the broader body of cannabinoid safety data in pets.
What CBG Is and How It Differs From CBD
CBG, short for cannabigerol, is often called the “parent cannabinoid” because it’s the chemical precursor from which other cannabinoids like CBD and THC are synthesized as the plant matures. By the time hemp is harvested, CBG levels are typically low, which is why it’s less common in pet products than CBD. Unlike THC, CBG does not produce a high and does not appear to cause the disorientation, vocalization, or wild-eyed pupil dilation that THC intoxication triggers in dogs.
Most CBG products marketed for pets contain broad-spectrum or full-spectrum hemp extracts, where CBG is one of several cannabinoids present alongside CBD, minor cannabinoids, and terpenes. The National Animal Supplement Council (NASC) defines broad-spectrum hemp extract as containing some or all naturally occurring plant compounds with THC processed to below 0.3%, while full-spectrum extracts retain all compounds including trace THC at that same threshold. If you’re specifically looking for CBG, check the product’s certificate of analysis to confirm how much cannabigerol is actually in each serving.
What the Research Shows
The most notable study on CBG in animals looked at its effect on eye pressure, a key factor in glaucoma. Researchers administered cannabigerol to cats both as single doses and through continuous delivery over nine days. Chronic administration produced a considerable reduction in intraocular pressure, which is the primary goal of glaucoma treatment. Importantly, CBG did not cause the neurotoxic effects that were observed with cannabinol (CBN), another cannabinoid tested in the same study. Even at doses of 10, 30, and 100 mg per kilogram of body weight in rats, CBG showed no neurotoxicity. The researchers concluded that CBG’s pressure-lowering effect on the eyes could be separated from the adverse brain and eye effects typically associated with cannabis compounds.
This is a meaningful finding for pet owners, because it suggests CBG has a wider safety margin than several other cannabinoids. However, these studies were conducted in cats and rats, not dogs. Dogs metabolize cannabinoids differently from other species, and they have a higher density of cannabinoid receptors in certain brain areas, which can make them more sensitive to some compounds. So while the safety signal from this research is encouraging, it doesn’t translate directly to a dosing recommendation for your dog.
Safety Profile in Pets
Post-market surveillance data collected by the NASC on hemp-derived supplements sold for dogs offers some reassurance. From 2010 through late 2023, the adverse event rate for hemp products was 2.10 per million administrations sold, with serious adverse events occurring at a rate of just 0.01 per million. These numbers cover hemp supplements broadly (not CBG isolates specifically), but they indicate that cannabinoid-containing pet products carry a low overall risk when manufactured to industry standards.
The side effects most commonly associated with cannabinoid use in dogs, drawn from veterinary reporting on cannabis exposure more broadly, include lethargy, changes in heart rate (either faster or slower than normal), altered blood pressure, slowed breathing, temperature fluctuations, excessive drooling, vomiting, and disorientation. These effects are most frequently seen with THC exposure or very high doses of cannabinoids, not typical CBG supplement use. Still, they represent the warning signs to watch for if your dog reacts poorly.
Choosing a CBG Product for Your Dog
The pet cannabinoid market is loosely regulated, which means product quality varies enormously. Look for products from companies that are NASC members, as these companies are required to register their products, submit labels for review, and report adverse events monthly through the NASC’s surveillance system. This doesn’t guarantee the product works, but it does mean someone is tracking safety data.
A certificate of analysis (COA) from a third-party lab is non-negotiable. The COA should confirm the actual CBG content matches what’s on the label, verify THC levels are below 0.3%, and screen for contaminants like heavy metals, pesticides, and residual solvents. If a company doesn’t make their COA easily accessible, that’s reason enough to choose a different product.
Because there are no established veterinary dosing guidelines for CBG specifically, most practitioners who recommend it suggest starting with a very low amount and increasing gradually while monitoring your dog’s behavior, appetite, and energy levels over several days. Dogs under 10 pounds will need substantially less than larger breeds, and individual sensitivity varies. Your dog’s response in the first few days is your best guide.
What CBG Won’t Do
CBG will not get your dog high. It also won’t replace veterinary treatment for serious conditions like glaucoma, epilepsy, or chronic pain. While the eye pressure research is intriguing, no veterinary organization currently recommends CBG as a standalone treatment for any diagnosed condition in dogs. It sits in the category of supplements: potentially helpful as part of a broader care plan, but not a substitute for proven therapies. If your dog has a specific health condition you’re hoping CBG will address, the most productive path is working with a veterinarian who is familiar with cannabinoid therapeutics in animals, as they can help you weigh the potential benefit against what’s already known to work.